ESR1 and neoplasm: A recently identified compound, ErSO, has been pre-clinically demonstrated to completely remove the tumor burden of therapy-resistant breast carcinoma through reinforcing the estrogen receptor (Y537S/D538G)-mediated pre-activated UPR [40].